Novavax Plays Down EU COVID Vaccine Contract Delay
Manufacturing Issues Not To Blame
Investors are anxious about the delay to Novavax’s deal with the EU, and want to know how and when it might file the vaccine with regulators.
You may also be interested in...
The UK wants to consolidate its rapid vaccine roll-out and its domestic supply chain via the alliance
As the coronavirus crisis continues to worsen across Europe, the EU authorities have come up with a new way of determining whether exports of coronavirus vaccines should be allowed.
The vaccine is 95.6% effective at preventing infection with the original COVID-19 strain and 85.6% effective at protecting against the B.1.1.7 strain, with an overall level of protection across the strains of 89.3%. Meanwhile, South Korea has drawn up a national vaccination plan and AstraZeneca is set to produce doses of its vaccine in Japan.